skip to primary navigationskip to content

Doctor Hassan Rahmoune

Doctor Hassan Rahmoune

Technical Officer

Senior Researcher (H-Index = 35)

Office Phone: +44 (0)1223 748999


Dr Hassan Rahmoune (PhD; h-index 35) has 31 years relevant  research experience translational sciences & personalised medicine  in both academia and biotech/Pharmaceutical settings. He has worked as a group leader in a pharmaceutical/Biotech (13 years) and senior researcher academic (14 years) environments and developed a solid research background (with over 90 scientific publications in a number of therapeutic areas such as respiratory, oncology, diabetes, CNS diseases and cryopreservation.

Research Interests

Therapeutic areas

Inflammation, respiratory, CNS and cardiovascular diseases, Oncology, diabetes and cryopreservation.


  • Drug target and biomarkers discovery/validation in preclinical and clinical settings  
  • Biochemistry, Cell biology, Carbohydrates (Glycobiology) and proteins chemistry
  • Cryopreservation and biopolymers

Research Supervision

  • Experience in leading personalised medicine and translational sciences research programs in pharmaceutical  and academic settings.
  • Experience in designing and delivering  personalised medicine based clinical trials (Cardiovascular/CNS and diabetes) 
  • Experience in supervising undergraduates, PhDs student, and research associates, junior and senior scientists.



Leadership and management development, stewardship, appraisal skills, competency skills, Health & Safety, project management in academia and biotech/clinical environments.

Other Professional Activities


Offers consultancy work related to design, running and analysis of preclinical and clinical studies. Particular expertise in the application of molecular biomarkers in various therapeutic areas (Inflammation/Diabetes and CNS diseases and Biobanking), with a focus on:

  • Innovative study design and introducing the scientific rigor and biological knowhow into pre-clinical (Target discovery) and clinical protocols/studies      (Experimental Medicine/Phase I-III clinical protocols)

    • Advising on the use of platform technology, biological assays for      translational biomarkers studies related to drug discovery/clinical      development.
    • Translational strategies leading to patient stratification, efficacy/toxicity and diagnostics/prognostic purposes
    • Follow up biological and clinical insights to maximize impact of the data and the utility of drug targets/biomarkers discovery and validation

Consultancy agreements are managed via Cambridge Enterprise, the university of Cambridge commercial arm.

Fluent speakers in four languages: English, French, Arabic and Spanish



  • affinity chromatography
  • biochemical engineering
  • ageing
  • drug delivery
  • biopharmaceuticals
  • vaccines
  • analytical biotechnology
  • pharamaceuticals

Key Publications

Published over 90  scientific manuscripts in respiratory, oncology, diabetes and CNS diseases.

- See


Not here?

Any new members of the department who are not listed here should please fill in